With our GPCR collection of 550 non-sensory GPCRs (300 human receptors and 250 mouse receptors) in native sequences, we provide functional assay for them in a single format, regardless of the subtypes of Gα proteins coupled. Click below for details or contact us for information about GPCRs of other animal species such as rats, rabbits, dogs, and macaque monkeys.
Filters Sort results
Reset Apply
Species | Receptor | Family | Assays | |
|---|---|---|---|---|
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Immunology/Infection ⋅ Hematology ⋅ Respiratory ⋅ à la carte |  Reference agonist: CCL1 EC50: 6.8 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Immunology/Infection ⋅ Hematology ⋅ Neurology ⋅ Respiratory ⋅ à la carte |  Reference agonist: CCL25 EC50: 15 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Hematology ⋅ à la carte |  Reference agonist: CCL27 EC50: 27 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Immunology/Infection ⋅ Gastrointestinal ⋅ à la carte |  Reference agonist: CXCL6 EC50: 20 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Immunology/Infection ⋅ Oncology ⋅ Hematology ⋅ Neurology ⋅ Ophthalmology ⋅ Cardiology ⋅ Respiratory ⋅ Gastrointestinal ⋅ Dermatology ⋅ Musculoskeletal ⋅ Urology/Reproduction ⋅ à la carte |  Reference agonist: CXCL6 EC50: 27 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Immunology/Infection ⋅ Oncology ⋅ Hematology ⋅ Ophthalmology ⋅ Cardiology ⋅ Respiratory ⋅ Gastrointestinal ⋅ Dermatology ⋅ Musculoskeletal ⋅ Urology/Reproduction ⋅ à la carte |  Reference agonist: CXCL11 EC50: 29 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Immunology/Infection ⋅ Oncology ⋅ Hematology ⋅ Endocrinology/Metabolism ⋅ Neurology ⋅ Ophthalmology ⋅ Cardiology ⋅ Respiratory ⋅ Gastrointestinal ⋅ Dermatology ⋅ Musculoskeletal ⋅ Urology/Reproduction ⋅ à la carte |  Reference agonist: cXCL12a EC50: 5.4 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Immunology/Infection ⋅ Hematology ⋅ Ophthalmology ⋅ Gastrointestinal ⋅ Dermatology ⋅ Musculoskeletal ⋅ à la carte |  Reference agonist: CXCL13 EC50: 36 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Immunology/Infection ⋅ Oncology ⋅ Hematology ⋅ Ophthalmology ⋅ Cardiology ⋅ Respiratory ⋅ Gastrointestinal ⋅ Dermatology ⋅ Musculoskeletal ⋅ Urology/Reproduction ⋅ à la carte |  Reference agonist: CXCL16 EC50: 3.9 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: - |  Reference agonist: XCL1 EC50: 43 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Immunology/Infection ⋅ Hematology ⋅ Neurology ⋅ Ophthalmology ⋅ Cardiology ⋅ Respiratory ⋅ Gastrointestinal ⋅ Dermatology ⋅ Musculoskeletal ⋅ Urology/Reproduction ⋅ à la carte |  Reference agonist: CX3CL1 EC50: 1.8 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety ⋅ Safety Premium ⋅ Oncology ⋅ Endocrinology/Metabolism ⋅ Psychiatry ⋅ Gastrointestinal ⋅ à la carte |  Reference agonist: CCK‐8 EC50: 17 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety Premium ⋅ Oncology ⋅ Endocrinology/Metabolism ⋅ Psychiatry ⋅ Neurology ⋅ Gastrointestinal ⋅ à la carte |  Reference agonist: CCK‐8 EC50: 490 pM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Respiratory ⋅ à la carte |  Reference agonist: C3a EC50: 3.7 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Immunology/Infection ⋅ Hematology ⋅ Respiratory ⋅ Musculoskeletal ⋅ à la carte |  Reference agonist: C5a EC50: 220 pM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Oncology ⋅ Psychiatry ⋅ Neurology ⋅ Dermatology ⋅ Musculoskeletal ⋅ à la carte |  Reference agonist: CRH EC50: 22 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Psychiatry ⋅ Cardiology ⋅ Gastrointestinal ⋅ à la carte |  Reference agonist: urocortin EC50: 23 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety ⋅ Safety Premium ⋅ Psychiatry ⋅ Neurology ⋅ Urology/Reproduction ⋅ à la carte |  Reference agonist: dopamine EC50: 260 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety ⋅ Safety Premium ⋅ Oncology ⋅ Endocrinology/Metabolism ⋅ Psychiatry ⋅ Neurology ⋅ Cardiology ⋅ Dermatology ⋅ Musculoskeletal ⋅ Urology/Reproduction ⋅ à la carte |  Reference agonist: dopamine EC50: 260 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety Premium ⋅ Psychiatry ⋅ Neurology ⋅ à la carte |  Reference agonist: dopamine EC50: 220 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety Premium ⋅ Psychiatry ⋅ Neurology ⋅ à la carte |  Reference agonist: dopamine EC50: 260 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety Premium ⋅ Psychiatry ⋅ Ophthalmology ⋅ à la carte |  Reference agonist: dopamine EC50: 250 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety ⋅ Safety Premium ⋅ Immunology/Infection ⋅ Oncology ⋅ Hematology ⋅ Endocrinology/Metabolism ⋅ Psychiatry ⋅ Neurology ⋅ Ophthalmology ⋅ Cardiology ⋅ Respiratory ⋅ Gastrointestinal ⋅ Dermatology ⋅ Musculoskeletal ⋅ Urology/Reproduction ⋅ à la carte |  Reference agonist: ET‐1 EC50: 5.5 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety Premium ⋅ Immunology/Infection ⋅ Oncology ⋅ Hematology ⋅ Endocrinology/Metabolism ⋅ Neurology ⋅ Ophthalmology ⋅ Cardiology ⋅ Respiratory ⋅ Gastrointestinal ⋅ Dermatology ⋅ Musculoskeletal ⋅ Urology/Reproduction ⋅ à la carte |  Reference agonist: ET‐1 EC50: 5.0 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Immunology/Infection ⋅ Hematology ⋅ à la carte |  Reference agonist: 7α,25‐dihydroxycholesterol EC50: 2.0 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ à la carte |  Reference agonist: fMLP EC50: 3.5 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Gastrointestinal ⋅ à la carte |  Reference agonist: WKYMVM EC50: 940 pM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: - |  Reference agonist: EC50: 5.9 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Endocrinology/Metabolism ⋅ à la carte |  Reference agonist: TAK‐875 EC50: 26 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ à la carte |  Reference agonist: propionate Na EC50: 880 µM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: - |  Reference agonist: acetic acid EC50: 100 µM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ à la carte |  Reference agonist: ZQ‐16 EC50: 2.2 µM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Ophthalmology ⋅ à la carte |  Reference agonist: GPR120 cpdA EC50: 1.9 µM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Psychiatry ⋅ Neurology ⋅ Musculoskeletal ⋅ à la carte |  Reference agonist: baclofen EC50: 9.4 µM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Psychiatry ⋅ Neurology ⋅ Musculoskeletal ⋅ à la carte | Reference agonist: baclofen EC50: 9.4 µM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ à la carte |  Reference agonist: galanin EC50: 1.9 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ à la carte |  Reference agonist: galanin EC50: 1.3 nM | ||
Human | Assay modes: - Panels: - | Reference agonist: EC50: | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Oncology ⋅ Endocrinology/Metabolism ⋅ Ophthalmology ⋅ Cardiology ⋅ Gastrointestinal ⋅ Musculoskeletal ⋅ à la carte |  Reference agonist: ghrelin EC50: 4.0 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Endocrinology/Metabolism ⋅ Musculoskeletal ⋅ à la carte |  Reference agonist: GHRH EC50: 2.0 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Endocrinology/Metabolism ⋅ à la carte |  Reference agonist: GIP EC50: 3.4 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Oncology ⋅ Hematology ⋅ Endocrinology/Metabolism ⋅ Ophthalmology ⋅ Cardiology ⋅ Gastrointestinal ⋅ Musculoskeletal ⋅ Urology/Reproduction ⋅ à la carte |  Reference agonist: GLP1‐(7‐36)amide EC50: 7.6 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ à la carte |  Reference agonist: GLP2 EC50: 7.4 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Endocrinology/Metabolism ⋅ à la carte |  Reference agonist: glucagon EC50: 6.3 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ à la carte |  Reference agonist: secretin EC50: 7.6 nM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Oncology ⋅ Endocrinology/Metabolism ⋅ Musculoskeletal ⋅ Urology/Reproduction ⋅ à la carte |  Reference agonist: FSH EC50: 8.6 ng/ml | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Oncology ⋅ Endocrinology/Metabolism ⋅ Dermatology ⋅ Urology/Reproduction ⋅ à la carte |  Reference agonist: rLHα/β EC50: 26 ng/ml | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Immunology/Infection ⋅ Oncology ⋅ Endocrinology/Metabolism ⋅ Ophthalmology ⋅ Respiratory ⋅ Dermatology ⋅ Musculoskeletal ⋅ Urology/Reproduction ⋅ à la carte |  Reference agonist: TSH EC50: 18 ng/ml | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Oncology ⋅ Endocrinology/Metabolism ⋅ Musculoskeletal ⋅ Urology/Reproduction ⋅ à la carte |  Reference agonist: LH‐RH EC50: 93 pM | ||
Human | Available Assay modes: Agonist ⋅ Inverse agonist ⋅ Antagonist ⋅ PAM ⋅ NAM Panels: Human non-orphan GPCRs ⋅ Safety ⋅ Safety Premium ⋅ Immunology/Infection ⋅ Psychiatry ⋅ Cardiology ⋅ Respiratory ⋅ Dermatology ⋅ à la carte |  Reference agonist: histamine EC50: 17 nM |
Contact Us
Send us a message via the form below or write to us at [email protected].
Ordering Process
Service flow chart
Request a quotation
We hear about the study outline and propose experiments. A non-disclosure agreement is optional.
STEP
1
Place an order
You place an order, ship your compounds to our lab, and pay the fee via bank transfer or by credit card.
STEP
2
Wait
The turnaround time can be as short as two weeks, depending on the study scale and design and the backlog of orders.
STEP
3
Receive the report
You receive the study report in PDF.
STEP
4